Earnings Releases·Nov 3, 2026, 4:19 PM ET

IFF — Third Quarter 2026 Earnings Summary

Consolidated net sales rose 4% year-over-year to $1.94 billion in Q3, while adjusted operating EBITDA increased 6% to $403 million; full-year 2026 sales and adjusted EBITDA guidance were both raised, with sales now projected at $7.5–$7.6 billion and EBITDA at $1.55–$1.60 billion.
The company completed a $500 million accelerated share repurchase program and confirmed the separation of the Food Ingredients business is on track to close by Q2 2027.
All three business segments (Taste, Health & Biosciences, Scent) delivered currency-neutral sales growth in Q3, though Q4 profitability is expected to be softer due to higher costs and reinvestments, particularly in Health & Biosciences.
First nine months of 2026 generated $820 million in operating cash flow and $371 million in free cash flow, both showing significant year-over-year increases.